SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

Strona główna・Stock List・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Open

SectorHealthcare

58 -1.02

Buy Sell

Overview

Share price change

24h

Current

Min

57.8

Max

58.6

Key metrics
By Trading Economics
Income	-33M 9.5M
Sales	-66M 152M
P/E Sector Avg	24.576 51.415
EPS	0.185
Profit margin	6.216
Employees	1,950
EBITDA	-45M 18M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+25.6% upside

Dividends
By Dow Jones
Next Earnings	23 lip 2026

Market Stats
By TradingEconomics
Market Cap	-1.1B 3B
Previous open	59.02
Previous close	58

News Sentiment

By Acuity

50%

174 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

51.1 / N/A Support & Resistance

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 maj 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 maj 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 maj 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 maj 2026, 23:28 UTC

Market Talk

Earnings

Global Forex and Fixed Income Roundup: Market Talk

19 maj 2026, 23:28 UTC

Market Talk

Earnings

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 maj 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 maj 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 maj 2026, 22:02 UTC

Earnings

ZTO Express (Cayman): Di Xu to Resign From Board

19 maj 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 maj 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 maj 2026, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 maj 2026, 21:37 UTC

Earnings

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 maj 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 maj 2026, 21:01 UTC

Earnings

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 maj 2026, 20:58 UTC

Earnings

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 maj 2026, 20:46 UTC

Hot Stocks

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 maj 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 maj 2026, 20:34 UTC

Earnings

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q EPS 5c >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q Sales $1.4B >JHX

19 maj 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 maj 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 maj 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 maj 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 maj 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 maj 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 maj 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 maj 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 maj 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

25.6% upside

12 Months Forecast

Average 73.6 EUR 25.6%

High 83 EUR

Low 64.2 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Laboratorios Farmaceuticos Rovi SA - Dist in the past 3 months.

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

174 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.